Liberty Global Ltd Class C vs Roivant Sciences Ltd. Common Shares — how do they compare? Liberty Global Ltd Class C trades at $8.45 (market cap $3.06B), while Roivant Sciences Ltd. Common Shares trades at $35.25 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 8.1× Liberty Global Ltd Class C's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| LBTYK | ROIV | |
|---|---|---|
Market Cap | $3.06B | $24.72B |
Volume | 2,508,956 | 6,279,442 |
Sector | Media | Health |
52-Week High | $12.67 | $41.81 |
52-Week Low | $8.75 | $16.04 |
Typical Hold Time | 21 Days | 1 Days |
Enterprise Value | $9.72B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
No Aura AI signal available yet.
Trailing returns across standard periods
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →